• BioMérieux discussed half-year 2026 results on July 28, led by CEO Pierre Boulud with CFO Guillaume Bouhours.
• Confirmed 2026 guidance: organic sales growth 3%-5% with CEBIT growth 0%-10%; Q4 respiratory season likely drives range positioning.
• H1 organic sales rose 0.2%; Q2 accelerated to 5%; H1 CEBIT fell 5% organically with 15.9% margin.
• Free cash flow reached nearly EUR 300 million; net cash was EUR 236 million at end-June; CAPEX view cut to about 8% of sales.
• Cut 2027-2028 targets to 3%-6% annual sales growth; expects CEBIT to outgrow sales; cited tighter healthcare budgets and higher cost pressures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMérieux SA published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.